When a cannabis company loses a lot of money every quarter, and has to sell real estate, cancel acquisitions, lay off staff, renegotiate existing financing to higher interest rates…
MMEN.C
Like the old Twilight Zone episode where helpful aliens leave behind a book called ‘To Serve Man’, only for us to find out later it’s a cookbook, investors have…
If you’ve been around this joint for a while, you’ll have seen us arguing folks would be silly to invest in MedMen (MMEN.C) if hanging on to your money…
MedMen (MMEN.C) owns 33 cannabis retail stores across 9 states. The stores have attractive exteriors, but the business inside is ugly. “MedMen reported another quarter of heavy losses [In…
The cannabis markets are sorely in need of some good news and better business practices. But if there’s a silver lining to all of this graft and double-dealing, it’s…
So the braintrusts over at MedMen (MMEN.C) have devised a new and novel way to staunch their company’s steady and consistent bleeding: they’re going to lay enough people off…
Cresco Labs (CL.C) and Origin House (OH.C) have updated the terms of their $1.1B acquisition, repricing the all-stock transaction to match declining share prices since the deal’s announcement in…
“Fiscal 2019 was a transformative year for Medmen, with over two million completed retail transactions to date and revenues increasing 227% year-over-year,” said Adam Bierman, Medmen co-founder and chief…
Sometimes a deal broken is a good deal for shareholders, especially if you give a red rat’s behind about your favourite company having enough money to survive the year….
In late August, Jim Cramer, host of CNBC’s Mad Money program, said he believes Cronos Group (CRON.C), and Aphria (APHA.T) are better investments than Canopy Growth (WEED.T). Cramer pointed to Canopy’s disappointing Q2 performance…